Angiotensin II receptor blockers reduce the progression of renal disease in patients with diabetic nephropathy, and reduce cerebrovascular and ischaemic heart disease mortality in hypertensive patients.
| Category | Examples | Nota bene |
|---|---|---|
| Angiotensin II receptor blockers | Losartan, valsartan, and candesartan | Hydrochlorothiazide (HCTZ) + Losartan is a common combination of antihypertensives |
- Mechanism of action
- Inhibition of angiotensin II type 1 (AT1) receptor → prevents angiotensin II mediated vasoconstriction and aldosterone secretion
- Reduced vasoconstriction
- Reduced aldosterone secretion
- Reduces sodium andwater retention
- Inhibition of angiotensin II type 1 (AT1) receptor → prevents angiotensin II mediated vasoconstriction and aldosterone secretion
- Indications
- Hypertension
- First-line antihypertensive in young patients when an ACEi is contraindicated
- First-line antihypertensive in young patients of African heritage
- Losartan reduces cardiovascular accidents and ischemic heart disease mortality in hypertensive patients
- Congestive heart failure
- Diabetic nephropathy
- Reduces the progression of renal disease in patients with diabetic nephropathy
- Hypertension
- Contraindications
- Pregnancy and Breastfeeding
- Renal vascular disease (bilateral stenosis or thrombosis)
- Adverse effect
- Cough
- Non-significant
- It is used as a substitute in patients who cannot tolerate ACEi cough
- First dose hypotension (orthostatic)
- Hyperkalemia
- Rash
- Dizziness
- Headache
- Fatigue
- Cough